Modafinil

Modafinil is a eugeroic used for treatment of narcolepsy, shift work sleep disorder, and excessive daytime sleepiness associated with obstructive sleep apnea.[7][8][12][13]

For obstructive sleep apnea, it is recommended that continuous positive airway pressure be appropriately used before considering starting modafinil to help with daytime sleepiness.[3]

Because of the risk for development of skin or hypersensitivity reactions and serious adverse psychiatric reactions, the European Medicines Agency has recommended that new patient prescriptions should be only to treat sleepiness associated with narcolepsy.[14]

Armed forces of several countries, including the United States, the United Kingdom, India and France, have expressed interest in modafinil as an alternative to amphetamine—the drug traditionally employed in combat situations or lengthy missions where troops face sleep deprivation. The French government indicated that the Foreign Legion used modafinil during certain covert operations.[15] The United Kingdom's Ministry of Defence commissioned research into modafinil[16] from QinetiQ and spent £300,000 on one investigation.[17] In 2011, the Indian Air Force announced that modafinil was included in contingency plans.[18]

In the United States military, modafinil has been approved for use on certain Air Force missions, and it is being investigated for other uses.[19] As of November 2012, modafinil is the only drug approved by the Air Force as a "go pill" for fatigue management (replacing prior use of amphetamine-based medications such as dextroamphetamine).[20]

The Canadian Medical Association Journal also reports that modafinil is used by astronauts on long-term missions aboard the International Space Station. Modafinil is "available to crew to optimize performance while fatigued" and helps with the disruptions in circadian rhythms and with the reduced quality of sleep astronauts experience.[21]

The addiction and dependence liabilities of modafinil are relatively low.[1][28] It shares biochemical mechanisms with addictive stimulant drugs, and some studies have reported it to have similar mood-elevating properties, although to a lesser degree.[28]

Monkeys will self-administer modafinil if they have previously been trained to self-administer cocaine.[28] As such, modafinil is classified by the United States FDA as a schedule IV controlled substance, a category for drugs with valid medical uses and low but significant addiction potential.[1][29]

Large-scale clinical studies have found no evidence of tolerance with modafinil at therapeutic dosages even with prolonged use (for 40 weeks and as long as three years).[30][31][32]

Modafinil-associated psychiatric reactions have occurred in those with and without a pre-existing psychiatric history.[33]

As of 2017, the therapeutic mechanism of action of modafinil for narcolepsy and sleep-wake disorders remains unknown.[35][36] Modafinil acts as an atypical, selective, and weak dopamine reuptake inhibitor which indirectly activates the release of orexin neuropeptides and histamine from the lateral hypothalamus and tuberomammillary nucleus, respectively all of which may contribute to heightened arousal.[35][36][37]

Research found that modafinil elevates dopamine levels in the hypothalamus in animals.[38] The locus of the monoamine action of modafinil was also the target of studies, with effects identified on dopamine in the striatum and, in particular, nucleus accumbens,[39][40] norepinephrine in the hypothalamus and ventrolateral preoptic nucleus,[41][42] and serotonin in the amygdala and frontal cortex.[43] Modafinil was screened at a large panel of receptors and transporters in an attempt to elucidate its pharmacology.[44] Of the sites tested, it was found to significantly affect only the dopamine transporter (DAT), acting as a dopamine reuptake inhibitor (DRI) with an IC₅₀ value of 4 μM.[44] Subsequently, it was determined that modafinil binds to the same site on the DAT as cocaine, but in a different manner.[45][46] In accordance, modafinil increases locomotor activity and extracellular dopamine concentrations in animals in a manner similar to the selective DRI vanoxerine (GBR-12909),[47] and also inhibits methamphetamine-induced dopamine release (a common property of DRIs, since DAT transport facilitates methamphetamine's access to its intracellular targets). As such, "modafinil is an exceptionally weak, but apparently very selective, [DAT] inhibitor".[48] In addition to animal research, a human positron emission tomography (PET) imaging study found that 200 mg and 300 mg doses of modafinil resulted in DAT occupancy of 51.4% and 56.9%, respectively, which was described as "close to that of methylphenidate".[49] Another human PET imaging study similarly found that modafinil occupied the DAT and also determined that it significantly elevated extracellular levels of dopamine in the brain, including in the nucleus accumbens.[50]

Modafinil has been described as an "atypical" DAT inhibitor, and shows a profile of effects that is very different from those of other dopaminergic stimulants.[51][52] For instance, modafinil produces wakefulness reportedly without the need for compensatory sleep, and shows a relatively low, if any,[53] potential for abuse.[48][51][52] Aside from modafinil, examples of other atypical DAT inhibitors include vanoxerine and benztropine, which have a relatively low abuse potential similar to modafinil.[51] These drugs appear to interact molecularly with the DAT in a distinct way relative to "conventional" DAT blockers such as cocaine and methylphenidate.[46][51]

Against the hypothesis that modafinil exerts its effects by acting as a DRI, tyrosine hydroxylase inhibitors (which deplete dopamine) fail to block the effects of modafinil in animals.[54] In addition, modafinil fails to reverse reserpine-induced akinesia, whereas dextroamphetamine, a dopamine releasing agent (DRA), is able to do so.[55] Moreover, one of the first published structure-activity relationship studies of modafinil found in 2012 that DAT inhibition did not correlate with wakefulness-promoting effects in animals among modafinil analogues, and a variety of analogues without any significant inhibition of the DAT still produced wakefulness-promoting effects.[56] Furthermore, "[the] neurochemical effects [of modafinil] and anatomical pattern of brain area activation differ from typical psychostimulants and are consistent with its beneficial effects on cognitive performance processes such as attention, learning, and memory",[53] and a study found that modafinil-induced increased locomotor activity in animals was dependent on histamine release and could be abolished by depletion of neuronal histamine, whereas those of methylphenidate were not and could not be.[38] As such, although it is established that modafinil is a clinically significant DRI, its full pharmacology remains unclear and may be more complex than this single property (i.e., may also include DAT-independent actions, such as "activation of the orexin system").[45][53]

In any case, there is nonetheless a good deal of evidence to indicate that modafinil is producing at least a portion of its wakefulness-promoting effects by acting as a DRI, or at least via activation of the dopaminergic system. In support of modafinil acting as a dopaminergic agent, its wakefulness-promoting effects are abolished in DAT knockout mice (although it is important to note that DAT knockout mice show D₁ and D₂ receptor and norepinephrine compensatory abnormalities, which might confound this finding), reduced by both D₁ and D₂ receptor antagonists (although conflicting reports exist),[55] and completely blocked by simultaneous inactivation of both D₁ and D₂ receptors.[48] In accordance, modafinil shows full stimulus generalization to other DAT inhibitors including cocaine, methylphenidate, and vanoxerine, and discrimination is blocked by administration of both ecopipam (SCH-39166), a D₁ receptor antagonist, and haloperidol, a D₂ receptor antagonist.[52] Partial substitution was seen with the DRA dextroamphetamine and the D₂ receptor agonist PNU-91356A, as well as with nicotine (which indirectly elevates dopamine levels through activation of nicotinic acetylcholine receptors).[52]

Modafinil may possess yet an additional mechanism of action. Both modafinil and its metabolite, modafinil sulfone, possess anticonvulsant properties in animals, and modafinil sulfone is nearly as potent as modafinil in producing this effect.[57] However, modafinil sulfone lacks any wakefulness-promoting effects in animals, indicating that a distinct mechanism may be at play in the anticonvulsant effects of both compounds.[57]

The (R)-enantiomer of modafinil, known as armodafinil, was also subsequently found to act as a D₂^High receptor partial agonist, with a K_i of 16 nM, an intrinsic activity of 48%, and an EC₅₀ of 120 nM, in rat striatal tissue.[58] The (S)-enantiomer is inactive with respect to the D₂ receptor.[58] Modafinil has been found to directly inhibit the firing of midbrain dopaminergic neurons in the ventral tegmental area and substantia nigra of rats via activation of D₂ receptors.[59]

An in vitro study predicts that modafinil may induce the cytochrome P450 enzymes CYP1A2, CYP3A4, and CYP2B6, as well as may inhibit CYP2C9 and CYP2C19.[5] It may also induce P-glycoprotein (Pgp), which may affect drugs transported by Pgp, such as digoxin.[60] The bioavailability of modafinil is greater than 80% of the administered dose. In vitro measurements indicate that 60% of modafinil is bound to plasma proteins at clinical concentrations of the drug. This percentage actually changes very little when the concentration is varied.[61]

None of these findings have been confirmed in vivo in clinical studies yet.

C_max (peak levels) occurs approximately 2–3 hours after administration. Food slows absorption, but does not affect the total AUC (Area Under the Curve – meaning food may slow absorption but the total amount of the chemical will be absorbed with or without food). Half-life is generally in the 10–12 hour range, subject to differences in CYP genotypes, liver function and renal function. It is metabolized in the liver, and its inactive metabolite is excreted in the urine. Urinary excretion of the unchanged drug ranges from 0% to as high as 18.7%, depending on various factors.[61]

The two major circulating metabolites of modafinil are modafinil acid (CRL-40467) and modafinil sulfone (CRL-41056).[62][4] Both of these metabolites have been described as inactive,[63] and neither appear to contribute to the wakefulness-promoting effects of modafinil.[62][4][64] However, modafinil sulfone does appear to possess anticonvulsant effects, and this is a property that it shares with modafinil.[57]

Modafinil and/or its major metabolite, modafinil acid, may be quantified in plasma, serum or urine to monitor dosage in those receiving the drug therapeutically, to confirm a diagnosis of poisoning in hospitalized patients or to assist in the forensic investigation of a vehicular traffic violation. Instrumental techniques involving gas or liquid chromatography are usually employed for these purposes.[66][67] As of 2011, it is not specifically tested for by common drug screens (except for anti-doping screens) and is unlikely to cause false positives for other chemically-unrelated drugs such as substituted amphetamines.

Reagent testing can be used to screen for the presence of modafinil in samples.

Modafinil is a highly researched compound, with many derivatives created and studied, some examples and their differences between dopamine, serotonin & norepinephrine affect is given in bundled table form below.

Pharmacology of modafinil's structural analogs

Modafinil analogs and their effects on the central nervous system.[70] Structure X1 X2 NR1R2 Action on CNS H H NHCH3 Stimulating H H NHCH(CH3)2 Stimulating H H NHC(CH3)3 Stimulating H H NHCH2CH3 Sedative H H Piperidine Sedative H H Morfoline Sedative 4-Cl H NH2 Stimulating 4-F 4-F NH2 Stimulating 4-F H NH2 Stimulating Thio- & Sulfinylacetamide Modafinil analogs[46] Structure X (di-benzene substitutions) Y (CH2 substitution) R (N-methyl terminating substitution) Ki [SE interval] (nM) @ DAT Ki [SE interval] (nM) @ SERT Ki [SE interval] (nM) @ NET Modafinil H S=O H 2600 (2430—2780) inactive inactive H S H 12400 (10800—14300) 14500 (11800—17700) inactive derived as 285000 (117000—690000) 3,3′-di-Cl S H 275 (257—295) inactive derived as 808000 (706000—924000) 45400 (39600—52000) H S CH3 19300 (17900—20800) inactive derived as 656000 (302000—1420000) 27200 (25700—28900) 4,4′-di-Cl S CH3 4130 (3620—4710) 10700 (7310—15700) 9770 (9170—10400) 4,4′-di-Br S CH3 3010 (2770—3260) 5720 (5320—6150) 11000 (9540—12600) H S allyl 8370 (6680—10500) inactive derived as 303000 (267000—344000) inactive derived as 171000 (88300—332000) H S n-propyl 20700 (20300—21100) inactive derived as 419000 (240000—729000) 68000 (53200—86900) 4,4′-di-F S n-propyl 11700 (10300—13200) 44200 (38700—50500) 59700 (51200—69600) 4,4′-di-Cl S n-propyl 1240 (1120—1380) 10100 (8900—11400) 7540 (6830—8330) 4,4′-di-Br S n-propyl 590 (550—632) 8900 (8150—9720) 10600 (9980—11300) H S cyclopropylmethyl 13600 (11900—15600) 20500 (17500—23900) inactive 4,4′-di-F S cyclopropylmethyl 6700 (5730—7830) 34000 (28800—40200) 57000 (51500—63000) 4,4′-di-Br S cyclopropylmethyl 975 (852—1110) 7030 (6040—8180) inactive H S n-butyl 23600 (20500—27100) inactive inactive 4,4′-di-F S n-butyl 6400 (5820—7050) 25500 (23300—28000) 56100 (53900—58500) 4,4′-di-Br S n-butyl 722 (659—792) 7090 (6990—8180) 7580 (7210—7970) H S 3-phenylpropyl 2020 (1990—2050) inactive inactive 4,4′-di-F S 3-phenylpropyl 442 (385—509) 3500 (2950—4160) inactive 4,4′-di-Cl S 3-phenylpropyl 223 (191—260) inactive inactive 4,4′-di-Br S 3-phenylpropyl 238 (202—280) 60700 (58400—63200) 35500 (31700—39800) H S 4-phenylbutyl 1150 (1020—1290) inactive 7960 (7590—8350) 4,4′-di-Br S 4-phenylbutyl 405 (348—471) inactive inactive 4,4′-di-CH3 S=O H 12700 (12400—13100) inactive inactive 4,4′-di-CF3 S=O H 35400 (34100—36700) not tested not tested 3,3′-di-F S=O H 5930 (4990—7060) inactive inactive 3,3′-di-Cl S=O H 881 (763—1020) inactive inactive H, 3-Br S=O H 550 (542—557) inactive inactive H S=O CH3 13100 (12600—13700) inactive inactive 4,4′-di-Br S=O 3-phenylpropyl 1280 (1160—1400) 892 (787—1010) inactive 4,4′-di-Cl S H 2200 (2060—2390) 38800 (36400—41300) 51400 (46000—57500)

Modafinil was originally developed in France by neurophysiologist professor Michel Jouvet and Lafon Laboratories. Modafinil originated with the late 1970s invention of a series of benzhydryl sulfinyl compounds, including adrafinil, which was first offered as an experimental treatment for narcolepsy in France in 1986. Modafinil is the primary metabolite of adrafinil, lacking the polar -OH group on its terminal amide,[71] and has similar activity to the parent drug but is much more widely used. It has been prescribed in France since 1994 under the name Modiodal, and in the US since 1998 as Provigil.

In 1998, modafinil was approved by the U.S. Food and Drug Administration[72] for the treatment of narcolepsy and in 2003 for shift work sleep disorder and obstructive sleep apnea/hypopnea[73] even though caffeine and amphetamine were shown to be more wakefulness promoting on the Stanford Sleepiness Test Score than modafinil.[36]

It was approved for use in the UK in December 2002. Modafinil is marketed in the United States by Cephalon, who originally leased the rights from Lafon, but eventually purchased the company in 2001.

Cephalon began to market armodafinil, the (R)-enantiomer of modafinil, in the United States in 2007. After protracted patent litigation and negotiations (see below), generic versions of modafinil became available in the US in 2012.

U.S. Patent 4,927,855 was issued to Laboratoire L. Lafon on May 22, 1990, covering the chemical compound modafinil. After receiving an interim term extension of 1066 days and pediatric exclusivity of six months, it expired on October 22, 2010. On October 6, 1994, Cephalon filed an additional patent, covering modafinil in the form of particles of defined size. That patent, U.S. Patent 5,618,845 was issued on April 8, 1997. It was reissued in 2002 as RE 37,516, which surrendered the 5618845 patent. With pediatric exclusivity, this patent expired on April 6, 2015.[74][75]

On December 24, 2002, anticipating the expiration of exclusive marketing rights, generic drug manufacturers Mylan, Teva, Barr, and Ranbaxy applied to the FDA to market a generic form of modafinil.[76] At least one withdrew its application after early opposition by Cephalon based on the RE 37,516 patent. There is some question of whether a particle size patent is sufficient protection against the manufacture of generics. Pertinent questions include whether modafinil may be modified or manufactured to avoid the granularities specified in the new Cephalon patent, and whether patenting particle size is invalid because particles of appropriate sizes are likely to be obvious to practitioners skilled in the art. However, under United States patent law, a patent is entitled to a legal presumption of validity, meaning that in order to invalidate the patent, much more than "pertinent questions" are required.

As of October 31, 2011, U.S. Reissue Patent No. RE 37,516 has been declared invalid and unenforceable.[77] The District Court for the Eastern District of Pennsylvania ruled that RE 37,516 was invalid because it: (1) was on sale more than one year prior to the date of the application in violation of 35 U.S.C. section 102(b); (2) was actually invented by someone else (the French company Laboratoire L. Lafon); (3) was obvious at the time the invention was made to a person having ordinary skill in the art under 35 U.S.C. section 103(a); and (4) failed the written description requirement of 35 U.S.C. section 112.[78] The patent was also found to be unenforceable due to Cephalon's inequitable conduct during patent prosecution.[78]

Cephalon made an agreement with four major generics manufacturers Teva, Barr Pharmaceuticals, Ranbaxy Laboratories, and Watson Pharmaceuticals between 2005 and 2006 to delay sales of generic modafinil in the US until April 2012 by these companies in exchange for upfront and royalty payments.[79] Litigation arising from these agreements is still pending including an FTC suit filed in April 2008.[80] Apotex received regulatory approval in Canada despite a suit from Cephalon's marketing partner in Canada, Shire Pharmaceuticals.[81][82] Cephalon has sued Apotex in the US to prevent it from releasing a genericized armodafinil (Nuvigil).[83] Cephalon's 2011 attempt to merge with Teva was approved by the FTC under a number of conditions, including granting generic US rights to another company;[84] ultimately, Par Pharmaceutical acquired the US modafinil rights as well as some others.[85]

In the United Kingdom, Mylan Inc. received regulatory approval to sell generic modafinil produced by Orchid in January 2010; Cephalon sued to prevent sale, but lost the patent trial in November.[86]

Modafinil is currently classified as a Schedule IV controlled substance under United States federal law; it is illegal to import by anyone other than a DEA-registered importer without a prescription.[87] However, one may legally bring modafinil into the United States in person from a foreign country, provided that he or she has a prescription for it, and the drug is properly declared at the border crossing. U.S. residents are limited to 50 dosage units (e.g., pills).[88] Under the US Pure Food and Drug Act, drug companies are not allowed to market their drugs for off-label uses (conditions other than those officially approved by the FDA);[89] Cephalon was reprimanded in 2002 by the FDA because its promotional materials were found to be "false, lacking in fair balance, or otherwise misleading".[90] Cephalon pleaded guilty to a criminal violation and paid several fines, including $50 million and $425 million fines to the U.S. government in 2008.[91][92]

In mainland China, modafinil is strictly controlled like other stimulants, such as amphetamines and methylphenidate. It has been classified as Class I psychotropic drug,[93] meaning that only doctors who have the right to prescribe narcotics and Class I psychotropic drugs (usually through special examination) can prescribe it for no more than three-day use (or seven-day use for control/extend-release products).[94] The first and only modafinil products was approved in November 2017,[95] but its marketing status in mainland China is still unknown.

In Japan, modafinil is Schedule I psychotropic drug.[96][97] Cephalon has licensed Alfresa Corporation to produce, and Mitsubishi Tanabe Pharma to sell modafinil products under the trade name Modiodal in Japan.[98] Also, there have been reported arrests of people who imported modafinil for personal use.[99][100]

Modafinil is considered a stimulant doping agent and as such is prohibited in sports competitions, in the same category as steroids.[101] Sanctions range from a simple warning to a 4.000 lei fine, as well as confiscation of the substance.

In Russia modafinil is Schedule II controlled substance like cocaine and morphine. Possession of few modafinil pills can lead to 3–10 years imprisonment.[102]

In Australia, modafinil is considered to be a Schedule 4 prescription-only medicine or prescription animal remedy.[103] Schedule 4 is defined as "Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription."

In Sweden, modafinil is classified as a schedule IV substance and possession is therefore illegal without prescription.[104]

The following countries do not classify modafinil as a controlled substance:

• Canada (not listed in the Controlled Drugs and Substances Act, but it is a Schedule F prescription drug,[105] so it is subject to seizure by Canada Border Services Agency)
• In Finland, modafinil is a prescription drug but not listed as a controlled substance.[106]
• In Denmark, modafinil is a prescription drug but not listed as a controlled substance.[107]
• Mexico (Not listed as a controlled substance, in the National Health Law)[108]
• South Africa Schedule V[109]
• United Kingdom (not listed in Misuse of Drugs Act so possession not illegal, but prescription required) [110]

Modafinil is sold under a wide variety of brand names worldwide, including Alertec, Alertex, Altasomil, Aspendos, Forcilin, Intensit, Mentix, Modafinil, Modafinilo, Modalert, Modanil, Modasomil, Modvigil, Modiodal, Modiwake, Movigil, Provigil, Resotyl, Stavigile, Vigia, Vigicer, Vigil, Vigimax, Wakelert and Zalux.[111]

The regulation of modafinil as a doping agent has been controversial in the sporting world, with high-profile cases attracting press coverage since several prominent American athletes have tested positive for the substance. Some athletes who were found to have used modafinil protested that the drug was not on the prohibited list at the time of their offenses.[112] However, the World Anti-Doping Agency (WADA) maintains that it was related to already banned substances. The Agency added modafinil to its list of prohibited substances on August 3, 2004, ten days before the start of the 2004 Summer Olympics.

Modafinil has received some publicity in the past when several athletes (such as sprinter Kelli White in 2004, cyclist David Clinger[113] and basketball player Diana Taurasi[114] in 2010, and rower Timothy Grant in 2015[115]) were discovered allegedly using it as a performance-enhancing doping agent. (Taurasi and another player, Monique Coker, tested at the same lab, were later cleared.[116]) It is not clear how widespread this practice is. The BALCO scandal brought to light an as-yet unsubstantiated (but widely published) account of Major League Baseball's all-time leading home-run hitter Barry Bonds' supplemental chemical regimen that included modafinil in addition to anabolic steroids and human growth hormone.[117] Modafinil has been shown to prolong exercise time to exhaustion while performing at 85% of VO_2max and also reduces the perception of effort required to maintain this threshold.[118] Modafinil was added to the World Anti-Doping Agency "Prohibited List" in 2004 as a prohibited stimulant (see Modafinil Legal Status).

Modafinil has been used non-medically as a "smart drug" by students, office workers, soldiers and transhumanists.[119][120][121][122][123] As a 'smart drug' it allegedly increases mental focus and helps evade sleep, properties which attract students, professionals in the corporate and tech fields, air-force personnel, surgeons, truck drivers and call-center workers. A survey of 2000 students in the UK in 2014 found that one in five people had used Modafinil to stay awake and study.

In the United States, an application to market modafinil for pediatric ADHD was submitted to the FDA, but approval was denied due to major concerns over the occurrence of Stevens–Johnson syndrome in clinical trials.[124]

Modafinil and armodafinil have been studied as a complement to antipsychotic medications in the treatment of schizophrenia. They have been consistently shown to have no effect on positive symptoms or cognitive performance.[125][126] A 2015 meta-analysis found that modafinil and armodafinil may slightly reduce negative symptoms in people with acute schizophrenia, though it does not appear useful for people with the condition who are stable, with high negative symptom scores.[126] Among medications demonstrated to be effective for reducing negative symptoms in combination with anti-psychotics, modafinil and armodafinil are among the smallest effect sizes.[127]

The prescribing information for Provigil notes that "There were no clinically significant differences in body weight change in patients treated with Provigil compared to placebo-treated patients in the placebo-controlled clinical trials."[128]

A 2015 review of clinical studies of possible nootropic effects in healthy people found: "... whilst most studies employing basic testing paradigms show that modafinil intake enhances executive function, only half show improvements in attention and learning and memory, and a few even report impairments in divergent creative thinking. In contrast, when more complex assessments are used, modafinil appears to consistently engender enhancement of attention, executive functions, and learning. Importantly, we did not observe any preponderances for side effects or mood changes."[8] A 2019 review of a single-dose of modafinil on mental function in healthy, non-sleep deprived people found a small effect and thus limited usefulness as a cognitive enhancer.[129] A 2020 review concluded that users' perception that modafinil is an effective cognitive enhancer is not supported by the evidence in healthy non-sleep-deprived adults.[130]

Modafinil has been used off-label in trials with people with symptoms of post-chemotherapy cognitive impairment, also known as "chemobrain", but a 2011 review found that it was no better than placebo.[131] As of 2015 it had been studied for use in multiple sclerosis associated fatigue, but the resulting evidence was weak and inconclusive.[132]

General anesthesia is required for many surgeries, but there may be lingering fatigue, sedation, and/or drowsiness after surgery has ended that lasts for hours to days. In outpatient settings wherein patients are discharged home after surgery, this sedation, fatigue and occasional dizziness is problematic. As of 2006, modafinil had been tested in one small (N=34) double-blind randomized controlled trial for this use.[133]